Icon ICLR reported solid second-quarter results highlighted by revenue exceeding $2 billion, representing an increase of 4% from the prior-year period. We have raised our fair value estimate to $243 ...
Icon competes in one of the most lucrative areas of the CRO market: long, complex trials that require hundreds if not thousands of patients and thus have ample room for missteps. Late-stage trials ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback